hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06361056, orgStudyIdInfo id: LCCC2140, briefTitle: Mobile Health App to Promote Participation of Black Women in Breast Cancer Clinical Trials, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-05-02, primaryCompletionDateStruct date: 2025-01, completionDateStruct date: 2026-01, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: UNC Lineberger Comprehensive Cancer Center, class: OTHER, descriptionModule briefSummary: This study explores the overall feasibility, impact, and satisfaction of using the "mHealth app" on clinic workflow for Black or African American women diagnosed with breast cancer.The "mHealth app" which can be used as a platform to share clinical trial education and communication, was created and tested in previous steps of this study., conditionsModule conditions: Breast Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Survey, interventions name: mHealth app, outcomesModule primaryOutcomes measure: Feasibility of Mobile Health Application (mHealth app)- subjects, primaryOutcomes measure: Feasibility of Mobile Health Application (mHealth app) - Clinicians and staff, secondaryOutcomes measure: Overall satisfaction, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UNC Lineberger Comprehensive Cancer Center, status: RECRUITING, city: Chapel Hill, state: North Carolina, zip: 27514, country: United States, contacts name: Lauren Matthews, role: CONTACT, phone: 919-843-5321, email: lauren_matthews@med.unc.edu, contacts name: Marjory Charlot, MD, MPH, MSc, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 35.9132, lon: -79.05584, hasResults: False
protocolSection identificationModule nctId: NCT06361043, orgStudyIdInfo id: 2023-01833, briefTitle: Conebeam CT-based Online Adaptive Radio-Therapy for Esophageal Cancer (ARTEC), acronym: ARTEC, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-20, primaryCompletionDateStruct date: 2027-02-28, completionDateStruct date: 2027-02-28, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Insel Gruppe AG, University Hospital Bern, class: OTHER, descriptionModule briefSummary: Despite multimodal therapy, patients with esophageal cancer have poor prognosis with 5-year overall survival around 25%. Considering tumor-related death as main reason for high mortality rate in those patients, treatment-related cardio-pulmonary toxicities could also play a role in this regard. Online adaptive radiotherapy offers the possibility for daily re-planning and therefore helps radiation oncologists to better spare the organs at risk and reduce radiation-induced toxicity. Tha aim of ARTEC is to assess the pulmonary toxicity in patients with esophageal cancer treated with online adaptive radiotherapy., conditionsModule conditions: Esophageal Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 30, type: ESTIMATED, outcomesModule primaryOutcomes measure: Number of patients with pulmonary toxicity, secondaryOutcomes measure: Number of patients with pathological complete response, secondaryOutcomes measure: Dosimetrical analysis between scheduled and adaptive plans, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Inselspital, University of Berne, Deparftment of Radio-Oncology, status: RECRUITING, city: Berne, zip: 3010, country: Switzerland, contacts name: Hossein Hammatazad, MD, role: CONTACT, phone: +41 31 632 26 32, email: hossein.hemmatazad@insel.ch, contacts name: Timo Nannen, role: CONTACT, phone: +41 31 632 90 74, email: timo.nannen@insel.ch, geoPoint lat: 46.94809, lon: 7.44744, hasResults: False
protocolSection identificationModule nctId: NCT06361030, orgStudyIdInfo id: HMPL-012-C2-PC01, briefTitle: Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2026-06-01, completionDateStruct date: 2027-06-01, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Wuhan Union Hospital, China, class: OTHER, descriptionModule briefSummary: To evaluate the efficacy and safety of surufatinib combined with gemcitabine plus nab-paclitaxel in patients with locally advance d pancreatic cancer, conditionsModule conditions: Pancreatic Cancer, conditions: Pancreatic Cancer Non-resectable, conditions: Pancreatic Ductal Adenocarcinoma, PDAC, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: surufatinib combined with gemcitabine plus nab-paclitaxel, outcomesModule primaryOutcomes measure: Surgical conversion rate, secondaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Disease control rate (DCR), secondaryOutcomes measure: R0 surgical conversion rate, secondaryOutcomes measure: progression free survival(PFS), secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Adverse Event, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, city: Wuhan, state: Hubei, zip: 430000, country: China, contacts name: Heshui Wu, role: CONTACT, phone: +86 137-2011-7761, email: heshuiwu@hust.edu.cn, contacts name: Heshui Wu, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.58333, lon: 114.26667, hasResults: False
protocolSection identificationModule nctId: NCT06361017, orgStudyIdInfo id: QNPY2022007, briefTitle: The Prediction of Hemorrhage Transformation by Cerebral Autoregulation in AIS Patient After Endovascular Thrombectomy, acronym: PHASE, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2022-03-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2026-03-01, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Xuanwu Hospital, Beijing, class: OTHER, descriptionModule briefSummary: This observational study was designed for observe the cerebral hemodynamics and dynamic cerebral autoregulation (dCA) after endovascular thrombectomy (EVT) in acute ischemic stroke (AIS) patients. And analysis the relationship between the dCA damage degree and hemorrhage transformation (HT) and clinical outcome.Patients: patients with AIS caused by middle cerebral artery or internal carotid artery occlusion who accepted EVT.dCA Examination: dCA examinations were performed at 24 hours, 48 hours, 72 hours, and 5 days after EVT.The objectives of the study were as follows: The changes of cerebral hemodynamics and parameters of dCA in different time periods after EVT were analyzed. So as to determine the correlation between hemodynamics and dCA change and HT and clinical outcome after EVT and to explore the predictors of HT and adverse clinical outcomes., conditionsModule conditions: Acute Ischemic Stroke, conditions: Endovascular Thrombectomy, conditions: Dynamic Cerebral Autoregulation, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: endovascular thrombectomy, outcomesModule primaryOutcomes measure: The occurrence of hemorrhage transformation, primaryOutcomes measure: Patients without hemorrhage transformation, primaryOutcomes measure: The occurrence of unfavorable outcome, primaryOutcomes measure: The occurrence of favorable outcome, secondaryOutcomes measure: The occurrence of long-term unfavorable outcome, secondaryOutcomes measure: The occurrence of long-term favorable outcome, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Vascular Ultrasonography, Xuanwu Hospital of Capital Medical University, city: Beijing, state: Beijing, zip: 100053, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06360991, orgStudyIdInfo id: DBS for TR-OCD, briefTitle: DBS for Treatment-resistant Obsessive-compulsive Disorder, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-20, primaryCompletionDateStruct date: 2028-12-31, completionDateStruct date: 2029-12-31, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Xuanwu Hospital, Beijing, class: OTHER, descriptionModule briefSummary: The primary purpose of this study is to investigate the effect of deep brain stimulation (DBS) implantation targeting the anteromedial region of subthalamic nucleus (amSTN), or nucleus accumbens (NAc), or bed nucleus of the stria terminalis (BNST), or ventral capsule/ventral striatum (VC/VS), or the ventral anterior limb of the internal capsule (vALIC) in patients with treatment-resistant obsessive-compulsive disorder (TR-OCD)., conditionsModule conditions: Obsessive-Compulsive Disorder (OCD), designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Deep brain stimulation (DBS), outcomesModule primaryOutcomes measure: Yale-Brown Obsessive Compulsive Scale (Y-BOCS): the change from baseline to 1 year in the Y-BOCS total score., secondaryOutcomes measure: Yale-Brown Obsessive Compulsive Scale (Y-BOCS): remission, response, and partial response rate, secondaryOutcomes measure: Hamilton Anxiety Scale (HAMA): the change from baseline to 2 weeks, 1 month, 3 months, 6 months, and 1 year in the HAMA total score., secondaryOutcomes measure: Hamilton Depression Rating Scale (HAMD-17): the changes of HAMD-17 scores and its subscales from baseline to 2 weeks, 1 month, 3 months, 6 months, and 1 year., secondaryOutcomes measure: Pittsburgh Sleep Quality Index (PSQI): the change of PSQI from baseline to Week 2, Month 1, Month 3, Month 6, and Month 1., secondaryOutcomes measure: Clinical Global Impression-Severity (CGI-S): the change from baseline to 2 weeks, 1 month, 3 months, 6 months, and 1 year in Clinical Global Impression-Severity (CGI-S), secondaryOutcomes measure: Clinical Global Impression-Improvement (CGI-I): CGI-I score at Week 2, Month 1, Month 3, Month 6, and Month 12., secondaryOutcomes measure: EuroQol-5 Dimension-level Scale (EQ-5D-5L): the change from baseline to Week 2, Month 1, Month 3, Month 6, and Month 12 in EQ-5D-5L., secondaryOutcomes measure: Young Mania Rating Scale (YMRS): the change from baseline to Week 2, Month 1, Month 3, Month 6, and Month 12., secondaryOutcomes measure: Safety as indicated by the number of Adverse Events Week 2, Month 1, Month 3, Month 6, and Month 12., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Xuanwu Hospital, Capital Medical University, city: Beijing, zip: 100053, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06360978, orgStudyIdInfo id: docetaxel as a radiosenstizer, briefTitle: Efficacy and Toxicity of Docetaxel as a Radiosenstizer in Head and Neck Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-06, completionDateStruct date: 2027-06, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: Head and neck cancer (HNC) is the seventh most common cancer globally, accounting for more than 660,000 new cases and 325,000 deaths annually. The overall incidence of HNC continues to rise, with a predicted 30% increase annually by 2030., this increase has been recorded across both developed and developing countries.Approximately 90% of HNCs are squamous cell carcinoma . The major risk factors of head and neck squamous cell carcinoma (HNSCC) are tobacco and heavy alcohol use and human papillomavirus infection . There has been a significant decline in smoking in high-income countries during the last few decades, which has led to a sharp decline in smoking related HNSCC . While increase in global incidence of human papillomavirus (HPV)-associated or positive (+) HNSCC Head and neck squamous cell carcinoma (HNSCC) is a highly challenging cancer, despite the advancements in treatment, the overall prognosis for HNSCC remains poor, with a five-year survival rate of around 50%.Chemoradiation is one of the treatment options for locally advanced head and neck cancers, the drug of choice for radiosensitization is cisplatin Although cisplatin-based chemoradiotherapy (CRT) is the standard of care for locally advanced head and neck squamous cell carcinoma (LAHNSCC), cisplatin is contraindicated in many patients because of age, diminished renal functions and hearing loss so docetaxel studied as an alternative radiosensitizer in this group.The addition of docetaxel to radiation improved DFS and OS in cisplatin-ineligible patients with LAHNSCC., conditionsModule conditions: Head and Neck Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Docetaxel, outcomesModule primaryOutcomes measure: progression free survival, secondaryOutcomes measure: incidence of treatment adverse events, secondaryOutcomes measure: Overall survival (OS), eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06360965, orgStudyIdInfo id: Shoufa2024-3-7045, briefTitle: Clinical Trial of Acupoint Application in Improving the Sequelae of Pelvic Inflammatory Disease and Chronic Pelvic Pain, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2026-03-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Beijing Hospital of Integrated Traditional Chinese and Western Medicine, class: OTHER, descriptionModule briefSummary: Chronic Pelvic Pain is one of the common gynecological symptoms, characterized by persistent and non periodic pain in the pelvic cavity and surrounding tissues. It is often seen as a sequelae of pelvic inflammatory diseases caused by the failure to receive timely and correct treatment. This study compares the effectiveness of warm meridians and relieve pain plaster in relieving the sequelae of pelvic inflammatory disease and chronic pelvic pain symptoms, and evaluates the safety of improved patches and traditional patches, further promoting it to community grassroots hospitals., conditionsModule conditions: Pelvic Inflammatory Disease, conditions: Chronic Pelvic Pain Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 102, type: ESTIMATED, armsInterventionsModule interventions name: Improved warm meridians and relieve pain plaster, interventions name: Traditional warm meridians and relieve pain plaster, interventions name: Placebo plaster, outcomesModule primaryOutcomes measure: Main symptoms (lower abdominal pain) improvement level (visual analogue scale), secondaryOutcomes measure: TCM syndrome score scale, secondaryOutcomes measure: Local physical sign rating scale, secondaryOutcomes measure: Pelvic masses and fluid accumulation, secondaryOutcomes measure: EuroQol Five Dimensions Questionnaire, secondaryOutcomes measure: Recurrence of abdominal pain during 1-month menstrual cycle was followed up., eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Beijing Hospital of Integrated Traditional Chinese and Western Medicine, status: RECRUITING, city: Beijing, country: China, contacts name: YuNa Liu, role: CONTACT, phone: 86-010-88223667, email: kjk882236672@163.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06360952, orgStudyIdInfo id: T23-03, briefTitle: A Comparator Study of a Tasso Device Blood Sample to Traditional Venous Blood Sample for CBC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2024-07-30, completionDateStruct date: 2024-07-30, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Tasso Inc., class: INDUSTRY, collaborators name: The Leukemia and Lymphoma Society, descriptionModule briefSummary: This study will evaluate the feasibility of using capillary blood samples collected with the Tasso device for analysis of CBC in diseased patients with leukemia, lymphoma, and/or other blood cell disorders.This investigation will include a minimum of 40 sample sets from unique patients., conditionsModule conditions: Leukopenia, conditions: Leukocytosis, conditions: Neutropenia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Tasso+ CBC, outcomesModule primaryOutcomes measure: Agreement between capillary and venous blood in the measurement of White Blood Cells and Absolute Neutrophil Count, secondaryOutcomes measure: Agreement between capillary and venous blood in the measurement of secondary biomarkers, otherOutcomes measure: Patient acceptance of Tasso device, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Lineberger Comprehensive Cancer Center, city: Chapel Hill, state: North Carolina, zip: 27599, country: United States, geoPoint lat: 35.9132, lon: -79.05584, hasResults: False
protocolSection identificationModule nctId: NCT06360939, orgStudyIdInfo id: ETH02659, briefTitle: Radiotherapy vs Catheter Ablation for Ventricular Tachycardia in Structural Heart Disease, acronym: Radioablate, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2026-04-15, completionDateStruct date: 2027-04-15, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Western Sydney Local Health District, class: OTHER, collaborators name: University of Sydney, collaborators name: National Heart Foundation, Australia, descriptionModule briefSummary: The goal of this randomized clinical trial is to test the efficacy of stereotactic body radiation therapy (SBRT) in treating ventricular tachycardia (VT) in patients with advanced structural heart disease. The main questions it aims to answer are:* What is the efficacy of SBRT compared to catheter ablation (CA) in achieving a ≥ 75% reduction in VT burden at 6 months* What is the comparable safety profile of SBRT vs CA Researchers will compare SBRT and CA (standard of care)., conditionsModule conditions: Ventricular Tachycardia, conditions: Cardiomyopathies, conditions: Arrhythmias, Cardiac, conditions: Ventricular Arrythmia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: SBRT, interventions name: CA, outcomesModule primaryOutcomes measure: VT burden, secondaryOutcomes measure: Recurrent sustained VT, secondaryOutcomes measure: VT storm, secondaryOutcomes measure: Absolute VT burden, secondaryOutcomes measure: Serious Adverse Events (SAE) and Adverse Events of Special Interest (AESI), secondaryOutcomes measure: ICD shocks, secondaryOutcomes measure: Hospitalization, secondaryOutcomes measure: All cause mortality, secondaryOutcomes measure: Cardiovascular Mortality, secondaryOutcomes measure: Composite outcome of VT recurrence/hospitalisation/death/ cardiac transplantation, secondaryOutcomes measure: Ventricular function, secondaryOutcomes measure: Quality of Life as per Short Form - 36 (SF-36) Score, secondaryOutcomes measure: Quality of Life as per Implantable Cardioverter Defibrillator Concerns Questionnaire (ICDC) score, secondaryOutcomes measure: Number of AADs, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06360926, orgStudyIdInfo id: 2024-A00526-41, briefTitle: Improvement Image Quality for SuperSonic® MACH Ultrasound System, acronym: MACH IQ, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2025-05, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: SuperSonic Imagine, class: INDUSTRY, descriptionModule briefSummary: The aim of this Study is to collect radiologist feedback to support the further development and improvement of the imaging modes implemented on the embedded software in the SuperSonic® Ultrasound System (including the probe)., conditionsModule conditions: Diagnosis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: SuperSonic® Ultrasound System, outcomesModule primaryOutcomes measure: Qualitative assessment of image quality, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False